Sundial Growers Inc.

Sundial Growers Inc. Earnings Recaps

SNDL Health Care 2 recaps
Q1 2026 Apr 30, 2026

Shares of SNDL fell 7.5% following Q1 earnings, as investors reacted negatively to declines in both the liquor and cannabis markets, worsening top-line contraction, and a drop in consolidated gross margins—particularly driven by weakness in cannabis operations. Persistent challenges in same-store sales and a year-over-year reduction in free cash flow added to concerns despite some margin gains in retail segments.

Key takeaways
  • Net revenue declined 4.4% year-over-year to $196 million, reflecting contraction in the liquor and cannabis businesses.
  • Gross profit fell by $3.8 million (down 6.8% year-over-year), with consolidated gross margin declining 70 basis points, attributed solely to ongoing softness in cannabis operations.
  • Both adjusted and unadjusted operating income remained negative, though operating losses narrowed compared to the prior year on improved OpEx control and lack of prior SunStream write-downs.
  • Free cash flow deteriorated to negative $7.6 million, a $6.5 million year-over-year decline, primarily due to working capital challenges in cannabis and higher CapEx.
  • Management points to improvement initiatives and newly added exclusive production contracts, but expects revenue growth to return only in the second half of 2026 as easier comps and these measures take effect.
Q3 2025 Nov 4, 2025

SNDL reported a strong third quarter of 2025, achieving record free cash flow and positive cumulative free cash flow for the first nine months of the year, despite facing a reported operating loss due to noncash items.

Key takeaways
  • Net revenue reached $244 million, a 3.1% year-over-year increase driven primarily by the Cannabis segment.
  • Free cash flow stood at $16.7 million for Q3, marking a $7.5 million improvement compared to the previous year, and bringing year-to-date total to $7.7 million.
  • Operating income was impacted by $11.9 million in noncash adjustments, including share-based compensation related to stock price increases.
  • Continued investment in growth, with the acquisition of 32 cannabis stores pending regulatory approval and plans to open several new retail locations in Q4.
  • Improvements in gross profit margins were countered by noncash inventory-related adjustments, highlighting operational challenges in the Cannabis Operations segment.